What If the Biopsy Picked the Biologic?

Dermatology diagnostics and therapeutic strategies for inflammatory skin conditions, particularly the differentiation between eczema and psoriasis, remain central to clinical practice. Dr. William Damsky from Yale University highlights the utility of RNA in situ hybridization (RISH) biomarker staining to clarify ambiguous biopsy results, which frequently impacts treatment decisions for patients with heterogeneous disease presentations. Beyond biopsy-based diagnostics, emerging research focuses on a non-invasive proteomic approach using detergent-based skin swabs to quantify cytokine profiles, potentially offering a more robust alternative to current gene expression testing. The discussion also addresses the management of Granuloma Annulare, noting that while often idiopathic, metabolic comorbidities are prevalent. Evidence suggests that TNF-alpha inhibitors and JAK inhibitors, such as generic tofacitinib, provide effective therapeutic options for generalized cases, shifting the standard of care away from traditional, less effective interventions.